Preparation and in-vitro ADME assays screening for rac-Rotigotine prodrugs towards alleviating PD/restless leg syndrome
Learn how Syngene customized ADME assays to identify rac-Rotigotine prodrugs with enhanced bioavailability, which could be used for treating Parkinson’s disease and restless leg syndrome.
Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts
Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions. These innovative molecules offer the potential to target “undruggable” proteins, but their complex structures present unique ADME (Absorption, Distribution, Metabolism, and Excretion) challenges that […]
Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery
Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras). Recently, we delved deep into the complexities of these fascinating molecules during our “DMPK Unraveled” webinar, and the insights shared were nothing short of transformative. […]
Elevating Patient Safety: Syngene’s Leadership in Nitrosamine Testing and Comprehensive Analytical Development Services
The pharmaceutical industry has been forced to reckon with the increasing discovery of nitrosamine impurities in drugs, compounds known for their carcinogenic potential. This became especially pronounced in 2018, when several widely used medications, such as Valsartan and Ranitidine, were recalled due to the presence of nitrosamines.
4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity. The global specialty polymer market, valued at over $87 billion globally (2024), is fast becoming the backbone of innovations in clean energy, medical devices, and high-performance electronics.
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science.
Paws, Pills and Progress – CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
SynWeave™: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones.
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
